120 related articles for article (PubMed ID: 7232839)
1. Immunorestoration of anergic cancer patients by azimexon.
Goutner A; Nasrat F; Bonardelle D; Rameau G
Recent Results Cancer Res; 1980; 75():47-52. PubMed ID: 7232839
[TBL] [Abstract][Full Text] [Related]
2. Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin.
Mathé G; Florentin I; Bruley-Rosset M; Goutner A; Serrou B
Recent Results Cancer Res; 1982; 80():331-3. PubMed ID: 6977171
[No Abstract] [Full Text] [Related]
3. The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.
Peter HH; Dziuba-Traber H; Boerner D
Eur J Cancer Clin Oncol; 1984 Mar; 20(3):353-9. PubMed ID: 6368246
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of intravenous azimexon therapy in human cancer.
Patt YZ; Hersh EM; Reuben J; Claghorn L; Mavligit G
J Biol Response Mod; 1986 Aug; 5(4):313-8. PubMed ID: 2874196
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of BM 12,531 (Prop. INN azimexon).
Bicker U
Recent Results Cancer Res; 1980; 75():147-52. PubMed ID: 7232826
[TBL] [Abstract][Full Text] [Related]
6. In vivo immunomodulating properties of two synthetic agents: azimexon and tuftsin.
Florentin I; Schulz J; Bruley-Rosset M; Kiger N; Martinez J; Mathé G
Recent Results Cancer Res; 1980; 75():153-61. PubMed ID: 6894500
[TBL] [Abstract][Full Text] [Related]
7. [Biological effects of leakadin].
Garin AM; Lichinitser MR; Dmitrieva NV; Rubtsov BI; Leneva NV
Vopr Onkol; 1988; 34(2):192-6. PubMed ID: 2964757
[TBL] [Abstract][Full Text] [Related]
8. Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by Azimexon.
Kreienberg R; Boerner D; Melchert F; Lemmel EM
J Immunopharmacol; 1983; 5(1-2):49-64. PubMed ID: 6606686
[TBL] [Abstract][Full Text] [Related]
9. Effects of BM 12,531 (azimexon) on in vitro lymphocyte and macrophage proliferation.
Hadden JW; Coffey RG
Recent Results Cancer Res; 1980; 75():162-4. PubMed ID: 7232828
[TBL] [Abstract][Full Text] [Related]
10. [A new feasibility of immune stimulation in diseases with reduced cell immunity? (author's transl)].
Pavelka K; Müller W
Cas Lek Cesk; 1981 May; 120(19):566-70. PubMed ID: 7237501
[No Abstract] [Full Text] [Related]
11. [Immune monitoring of the cancer patient: suppressor cells and NK cells].
Goutner A; Thomas Y; Huchet R; Mathé G
C R Seances Soc Biol Fil; 1980; 174(4):750-5. PubMed ID: 6159953
[TBL] [Abstract][Full Text] [Related]
12. Effect of the immunomodulant 2-cyanaziridine derivative BM 41.332 on adjuvant arthritis in the rat.
Bicker U
Arzneimittelforschung; 1982; 32(7):746-52. PubMed ID: 6889876
[TBL] [Abstract][Full Text] [Related]
13. Ciamexon-treatment in endocrine ophthalmopathy.
Utech C; Wulle KG; Pfannenstiel P; Adam W
Acta Endocrinol Suppl (Copenh); 1987; 281():342-3. PubMed ID: 3303793
[TBL] [Abstract][Full Text] [Related]
14. Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC).
Patt YZ; Mansell PW; Reuben JM; Claghorn L; Li S; Gehan E; Hersh EM
AIDS Res; 1986; 2(3):191-209. PubMed ID: 3755909
[TBL] [Abstract][Full Text] [Related]
15. Structural studies of immunomodulators. Part 2: Crystal structure and conformation of azimexon (BM 12.531) an immunostimulant and an anti-tumor drug.
Srikrishnan T
Anticancer Drug Des; 1990 May; 5(2):213-20. PubMed ID: 2357266
[TBL] [Abstract][Full Text] [Related]
16. Influence of ciamexon on blood glucose and insulin requirement in newly manifested type I diabetics. Results of a pilot study.
Hogan M; Beyer J; Stuermer W; Weber P; Schrezenmeier J
Arzneimittelforschung; 1988 Aug; 38(8):1185-9. PubMed ID: 3058137
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy: concepts and nursing implications.
McCalla JL
Nurs Clin North Am; 1976 Mar; 11(1):59-71. PubMed ID: 1083016
[TBL] [Abstract][Full Text] [Related]
18. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection.
Caiaffa WT; Graham NM; Galai N; Rizzo RT; Nelson KE; Vlahov D
Arch Intern Med; 1995 Oct; 155(19):2111-7. PubMed ID: 7575072
[TBL] [Abstract][Full Text] [Related]
19. [Effects of azimexon on interleukin 2 and interleukin 1 production in vitro].
Song JP; Qian DH
Zhongguo Yao Li Xue Bao; 1988 Sep; 9(5):468-71. PubMed ID: 3265267
[No Abstract] [Full Text] [Related]
20. Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon.
Patt YZ; Mavligit GM; Reuben J; Mansell PW; Li S; Newell G; Talpaz M; Hersh EM
J Biol Response Mod; 1986 Jun; 5(3):263-9. PubMed ID: 3088215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
